Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation of two Phase II clinical studies, SHINING and REBUILDING, for its Category 1 innovative polypeptide drug candidate RAY1225. These studies aim to assess the efficacy of RAY1225 as a treatment for type 2 diabetes and for obese/overweight patients.
RAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug that exhibits dual activation activity on both the GLP-1 receptor and the glucose-dependent insulin-promoting polypeptide (GIP) receptor. The drug is in development with the goal of lowering blood sugar levels, reducing weight, treating metabolic syndrome, and addressing other related conditions. Notably, there is currently no similar product approved for weight loss in China, making RAY1225 a potentially significant advancement in the country’s pharmaceutical landscape.
The commencement of these Phase II studies signifies a significant step for Zhongsheng Pharmaceutical as it seeks to expand its pipeline and contribute to the global effort in developing innovative treatments for diabetes and obesity.- Flcube.com
